Carcinogenic alterations in murine liver, lung, and uterine tumors induced by in utero exposure to ionizing radiation

Molecular Carcinogenesis

Volumn 21, Issue 2, 1998, Pages 100-110

  Lumniczky, Katalin ^a   Antal, Sára ^a   Unger, Emil ^a   Wunderlich, Livius ^a   Hidvégi, Egon J ^a   Sáfrány, Géza ^a  

^a National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

Author keywords

Loss of heterozygosity; Multiple tumor suppressor; Myc; p53; Ras

Indexed keywords

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CHERNOBYL ACCIDENT; CHROMOSOME 11; CHROMOSOME LOSS; CONTROLLED STUDY; GENE LOCUS; GENETIC HETEROGENEITY; IONIZING RADIATION; LIVER CARCINOGENESIS; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; NUCLEAR ACCIDENT; ONCOGENE C MYC; ONCOGENE RAS; POINT MUTATION; PRENATAL EXPOSURE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERUS CARCINOMA;

ANIMALS; DNA, NEOPLASM; FEMALE; GAMMA RAYS; GENE AMPLIFICATION; GENES, P16; GENES, P53; GENES, RAS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICROSATELLITE REPEATS; NEOPLASMS, RADIATION-INDUCED; POINT MUTATION; PREGNANCY; RECEPTORS, CHOLINERGIC; RNA, NEOPLASM; UTERINE NEOPLASMS;

ANIMALIA; MURINAE; TRIXIS;

EID: 0031887964     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199802)21:2<100::AID-MC4>3.0.CO;2-R     Document Type: Article

References (57)

1. Burns FJ, Upton AC, Silini G (eds). Radiation Carcinogenesis and DMA Alterations. Plenum Publishing, New York, 1986.
2. Muratova RM, Zhilenko MI, lakovleva NI, et al. Perinatal care for the fetus in woman exposed to ionizing radiation after the Chernobyl nuclear plant accident. Med Tr Prom Ekol 10:25-27, 1994.
3. Laziuk GI, Kirillova IA, Dubrova JE, Novikova IV. Incidence of developmental abnormalities among human fetuses in different regions of Belorussia after the Chernobyl accident. Genetika 30:1268-1273, 1994.
4. Petridou E, Trichopoulos D, Dessypris N, et al. Infant leukaemia after in utero exposure to radiation from Chernobyl. Nature 382:352-353, 1996.
5. Dubrova YL, Nesterov VN, Krouchinsky NG, et al. Human minisatellite mutation rate after the Chernobyl accident. Nature 380:683-688, 1996.
6. Sloan SR, Newcomb EW, Pellicer A. Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation. Mol Cell Biol 10:405-408, 1990.
7. Mothersill C, Seymour CB, Harney J, Hennessy TP. High levels of stable p53 protein and the expression of c-myc in cultured human epithelial tissue after cobalt-60 irradiation. Radiat Res 137:317-322, 1994.
8. Garte SJ, Burns FJ, Ashkenazi-Kimmel T, Felber M, Sawey MJ. Amplification of the c-myc oncogene during progression of radiation-induced rat skin tumors. Cancer Res 50:3073-3077, 1990.
9. Sturm SA, Strauss GP, Adolph S, Hameister M, Erfle V. Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas. Cancer Res 50:4146-4153, 1990.
10. Gjerset RA, Arya J, Volkman S, Haas M. Association of induction of a fully tumorigenic phenotype in murine radiation-induced T-lymphoma cells with loss of differentiation antigens, gain of CD44, and alterations in p53 protein levels. Mol Carcinog 5:190-198, 1992.
11. Strauss PG, Mitreiter K, Zitzelsberger M, et al. Elevated p53 RNA expression correlates with incomplete osteogenic differentiation of radiation-induced murine osteosarcomas. Int J Cancer 50:252-258, 1992.
12. Kamb A, Gruis NA, Weaver FJ, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994.
13. ink4b genes. Oncogene 11:635-645, 1995.
14. Santos J, Perez-de-Castro I, Herranz M, Pellicer A, Fernandez-Piqueras J. Allelic losses on chromosome 4 suggest the existence of a candidate tumor suppressor gene region of about 0.6 cM in gamma - Radiation-induced mouse primary thymic lymphomas. Oncogene 12:669-676, 1996.
15. Dietrich WF, Miller JC, Steen RG, et al. A genetic map of the mouse with 4,006 simple sequence length polymorphisms. Nat Genet 7:220-245, 1994.
16. Wieseman RW, Cochran C, Dietrich W, Lander ES, Söderkvist P. Allelotyping of butadiene-induced lung and mammary adeno- carcinomas of B6C3F1 mice: Frequent losses of heterozygosity in regions homologous to human tumor suppressor genes. Proc Natl Acad Sci USA 91:3759-3763, 1994.
17. Herzog CR, Wiseman RW, You M. Deletion mapping of a puta- tive tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer Res 54:4007-4010, 1994.
18. Lumniczky K, Antal S, Unger E, Hidvégi EJ, Sáfrány G. Oncogenic changes in murine lymphoid tumors induced by in utero exposure to ionizing radiation. Radiat Oncol Investig 5:158-162, 1997
19. Lumniczky K, Sáfrány G. Simultaneous isolation of both RNA and DNA from many small tissue samples. Acta Biol Hung 48:253-257, 1997.
20. Chomczynski P, Sacchi N. Single step method of RNA isolation by acidic guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
21. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1982.
22. Zakut-Houri R, Oren M, Bienz B, Lavie V, Hazum S, Givol D. A single gene and a pseudogene for the cellular tumor antigen p53. Nature 306:594-597, 1983.
23. Colby WW, Chen EY, Smith DH, Levinson AD. Identification and nucleotide sequence of a human locus homologous to the vmyc oncogene of avian myelocytomatosis virus MC29. Nature 301:722-725, 1983.
24. Ellis RW, DeFeo D, Shih TY, et al. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 292:506-511, 1981.
25. McCoy MS, Bargmann CI, Weinberg RA. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol Cell Biol 4:1577-1582, 1984.
26. Guerrero I, Villasante A, D'Eustachio P, Pellicer A. Isolation, characterization and chromosome assignment of mouse N-ras gene from carcinogen-induced thymic lymphoma. Science 225:1041-1043, 1984.
27. Minty AJ, Caravatti M, Robert B, et al. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse α-actin mRNA. J Biol Chem 256:1008-1014, 1981.
28. Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res 52:6400-6403, 1992.
29. Pierceall WE, Kripke ML, Ananthaswamy HN. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res 52:3946-3951, 1992.
30. Zhuang SM, Eklund LK, Cohran C, Rao GN, Wiseman RG, Söderkvist P. Allelotype analysis of 2′ ,3′-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice. Cancer Res 56:3338-3343, 1996.
31. Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M. Mutational activation of the c-H-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 88:911-915, 1991.
32. Dragani TA, Manenti G, Colombo BM, et al. Incidence of mutations at codon 61 of the H-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene 6:333-338, 1991.
33. Stanley LA, Devereux TR, Foley J, et al. Proto-oncogene activation in liver tumors of hepatocarcinogenesis-resistant strains of mice. Carcinogenesis 13:2427-2433, 1992.
34. Devereux TR, Foley JF, Maronpot RR, Kari F, Anderson MW. Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride. Carcinogenesis 14:795-801, 1993.
35. Richardson KK, Helvering LM, Copple DM, et al. Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and card- nomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986. Carcinogenesis 13:935-941, 1992.
36. Hsu IC, Metcalf RA, Sun T, et al, Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428, 1991.
37. Goodrow TL, Storer RD, Leander KR, Prahalada SR, van Zwieten MJ, Bradley MO. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction-direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol Carcinog 5:9-15, 1992.
38. Kress S, König J, Schweizer J, Löhrke H, Bauer-Hofman R, Schwarz M. p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol Carcinog 6:148-158, 1992.
39. Hegi ME, Soderkvist P, Foley JF, et al. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis 14:803-810, 1993.
40. Davis LM, Caspary WJ, Sakallah SA, et al. Loss of heterozygosity in spontaneous and chemically induced tumors of the B6C3F1 mouse. Carcinogenesis 15:1637-1645, 1994.
41. Hegi ME, Devereux TR, Dietrich WF, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res 54:6257-6264, 1994.
42. Hsieh LL, Hsiao WL, Peraino C, Maronpot RR, Weinstein IB. Expression of retroviral sequences and oncogenes in rat liver tumors induced by diethylnitrosamine. Cancer Res 47:3421-3424, 1987.
43. Patt S, Thiel G, Maas S, et al. Chromosomal changes and correspondingly altered proto-oncogene expression in human gliomas: Value of combined cytogenetic and molecular genetic analysis. Anticancer Res 13:113-118, 1993.
44. Sun Y, Hegamyer G, Nakamura K, Kim H, Oberley LW, Colburn NH. Alterations of the p53 tumor suppressor gene in transformed mouse liver cells. Int J Cancer 55:952-956, 1993.
45. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665s-2669s, 1992.
46. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancers from uranium miners. Lancet 339:576-580, 1992.
47. McDonald JW, Taylor JA, Watson MA, Saccomanno G, Devereux TR. p53 and K-ras in radon associated lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev 4:791-793, 1995.
48. Stegelmeier BA, Gillett NA, Rebar AH, Kelly G. The molecular progression of plutonium-239 induced rat lung Carcinogenesis: Ki-ras expression and activation. Mol Carcinog 4:43-51, 1991.
49. Loktionov A, Hollstein M, Martel N, et al. Tissue-specific activating mutations of Ha- and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA. Mol Carcinog 3:134-140, 1990.
50. 6-methylguanine DMA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog 8:177-185, 1993.
51. Takahashi T, Nau MM, Chiba I, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494, 1989.
52. Kelly G, Stegelmeier BL, Hahn FF. p53 alterations in plutonium-induced F344 rat lung tumors. Radiat Res 142:263-269, 1995.
53. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Andersson M. p53 mutation hotspots in radon-associated lung cancer. Lancet 343:86-87, 1994.
54. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55:2968-2971, 1995.
55. DeVos S, Wilczynski SP, Fleischhacker M, Koeffler P. p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 54:205-208, 1994.
56. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83:118-124, 1994.
57. Patterson H, Gill S, Fisher C, et al. Abnormalities of the p53, MDM2, and DCC genes in human leiomyosarcomas. Br J Cancer 69:1052-1058, 1994.